-
公开(公告)号：US11993570B2
公开(公告)日：2024-05-28
申请号：US17900412
申请日：2022-08-31
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Satoru Matsumoto , Yoshimasa Omori , Masahiro Mineno , Yasutaka Hoashi
IPC: C07C229/12 , A61K9/16 , C07C69/533 , C12N15/113
CPC classification number: C07C69/533 , A61K9/1617 , C12N15/113
Abstract: The present invention provides a technique that enables introduction of active ingredients, in particular, nucleic acids, into cells with superior efficiency; and cationic lipids, etc., for use in the technique. The compound or a salt thereof according to the present invention is a compound represented by formula (I) or a salt thereof. In formula (I), n represents an integer of 2 to 5, R represents a linear C1-5 alkyl group, a linear C7-11 alkenyl group, or a linear C11 alkadienyl group, and wavy lines each independently represent a cis-bond or a trans-bond.
-
公开(公告)号：US09701623B2
公开(公告)日：2017-07-11
申请号：US14346924
申请日：2012-09-27
Inventor： Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Nair , Muthusamy Jayaraman , Satoru Matsumoto
IPC: C07C271/16 , C07C43/04 , C07C235/74 , C12N15/113 , C07C237/06 , A61K9/127 , A61K47/48
CPC classification number: C07C271/16 , A61K9/1271 , A61K31/713 , A61K47/60 , C07C43/04 , C07C235/74 , C07C237/06 , C12N15/1137 , C12N2310/14 , C12N2320/32
Abstract: The disclosure relates to di-aliphatic substituted PEGylated lipids and to methods of their preparation. The disclosure also relates to lipid conjugates containing di-aliphatic substituted PEGylated lipids, and to the use of di-aliphatic substituted PEGylated-lipid conjugates in drug delivery.
-
Patent Agency Ranking
公开(公告)号：US20150203446A1
公开(公告)日：2015-07-23
申请号：US14346924
申请日：2012-09-27
Inventor： Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Nair , Muthusamy Jayaraman , Satoru Matsumoto
IPC: C07C271/16 , C07C43/04 , C07C237/06 , C12N15/113 , C07C235/74
CPC classification number: C07C271/16 , A61K9/1271 , A61K31/713 , A61K47/60 , C07C43/04 , C07C235/74 , C07C237/06 , C12N15/1137 , C12N2310/14 , C12N2320/32
Abstract: The disclosure relates to di-aliphatic substituted PEGylated lipids and to methods of their preparation. The disclosure also relates to lipid conjugates containing di-aliphatic substituted PEGylated lipids, and to the use of di-aliphatic substituted PEGylated-lipid conjugates in drug delivery.
Abstract translation: 本公开涉及二脂族取代的聚乙二醇化脂质及其制备方法。 本公开还涉及含有二脂族取代的聚乙二醇化脂质的脂质缀合物，以及在药物递送中使用二脂族取代的聚乙二醇化 - 脂质缀合物。
-
公开(公告)号：US20230257338A1
公开(公告)日：2023-08-17
申请号：US17900412
申请日：2022-08-31
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Satoru Matsumoto , Yoshimasa Omori , Masahiro Mineno , Yasutaka Hoashi
IPC: C07C69/533 , A61K9/16 , C12N15/113
CPC classification number: C07C69/533 , A61K9/1617 , C12N15/113
Abstract: The present invention provides a technique that enables introduction of active ingredients, in particular, nucleic acids, into cells with superior efficiency; and cationic lipids, etc., for use in the technique. The compound or a salt thereof according to the present invention is a compound represented by formula (I) or a salt thereof. In formula (I), n represents an integer of 2 to 5, R represents a linear C1-5 alkyl group, a linear C7-11 alkenyl group, or a linear C11 alkadienyl group, and wavy lines each independently represent a cis-bond or a trans-bond.
-
公开(公告)号：US20220098142A1
公开(公告)日：2022-03-31
申请号：US17267179
申请日：2019-08-08
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Satoru Matsumoto , Yoshimasa Omori , Masahiro Mineno , Yasuhiro Sawai , Nozomu Kakimoto , Yusutaka Hoashi
IPC: C07C229/12 , C12N15/113 , A61K9/51
Abstract: The present invention provides a technique capable of transferring an active ingredient, particularly, a nucleic acid, to a cell with excellent efficiency and a cationic lipid for use in this technique, etc. The cationic lipid of the present invention is a compound represented by the formula (I) or a salt thereof. n1 represents an integer of 2 to 6, n2 represents an integer of 0 to 2, n3 represents an integer of 0 to 2, L represents —C(O)O— or —NHC(O)O—, Ra represents a linear C5-13 alkyl group, a linear C13-17 alkenyl group or a linear C17 alkadienyl group, Rb represents a linear C2-9 alkyl group, Rc represents a hydrogen atom or a linear C2-9 alkyl group, Rd represents a hydrogen atom or a linear C2-9 alkyl group, Re represents a linear C2-9 alkyl group, and Rf represents a linear C2-9 alkyl group.
-
公开(公告)号：US20200331841A1
公开(公告)日：2020-10-22
申请号：US16958244
申请日：2018-12-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Satoru Matsumoto , Yoshimasa Omori , Masahiro Mineno , Yusutaka Hoashi
IPC: C07C69/533 , C12N15/113 , A61K9/16
Abstract: The present invention provides a technique that enables introduction of active ingredients, in particular, nucleic acids, into cells with superior efficiency; and cationic lipids, etc., for use in the technique. The compound or a salt thereof according to the present invention is a compound represented by formula (I) or a salt thereof. In formula (I), n represents an integer of 2 to 5, R represents a linear C1-5 alkyl group, a linear C7-11 alkenyl group, or a linear C11 alkadienyl group, and wavy lines each independently represent a cis-bond or a trans-bond.
-
公开(公告)号：US20220145329A1
公开(公告)日：2022-05-12
申请号：US17267602
申请日：2019-08-08
Applicant: Kyoto University , Takeda Pharmaceutical Company Limited
Inventor： Yoshinori Yoshida , Kenji Miki , Satoru Matsumoto
Abstract: The present invention provides means which is excellent in efficiency with which a nucleic acid is introduced to cardiac muscle cells, especially a transfection method. A method for transfection of a nucleic acid into a cardiac muscle cell of the present invention comprises a step of contacting a composition comprising: a compound represented by the formula (I) or a salt thereof; a structured lipid; and a nucleic acid, with a cell population comprising cardiac muscle cells.
-
-
-
-
-
-
Search Results
7
records
(took 0.023 seconds)
